Expression of EGFR and HPV-associated p16 in oropharyngeal carcinoma: Correlation and influence on prognosis after radiotherapy in the randomized DAHANCA 5 and 7 trials

被引:47
|
作者
Lassen, Pernille [1 ]
Overgaard, Jens [1 ]
Eriksen, Jesper Grau [2 ]
机构
[1] Aarhus Univ Hosp, Dept Expt Clin Oncol, Aarhus, Denmark
[2] Odense Univ Hosp, Dept Oncol, DK-5000 Odense C, Denmark
关键词
EGFR; HPV; p16; HNSCC; Radiotherapy; SQUAMOUS-CELL CARCINOMA; GROWTH-FACTOR RECEPTOR; NECK-CANCER; HUMAN-PAPILLOMAVIRUS; TUMOR DIFFERENTIATION; SUPRAGLOTTIC LARYNX; TREATMENT TIME; HEAD; SURVIVAL; SMOKING;
D O I
10.1016/j.radonc.2013.08.036
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: EGFR and HPV-associated p16 are among the most investigated biomarkers in head and neck cancer. The aim was to investigate the correlation and interaction between these two markers and to evaluate their potential prognostic significance when combined. Materials and methods: 336 Oropharyngeal carcinomas treated with primary radiotherapy (66-68 Gy, 2 fx/day, 10-12 Gy/week) and with known EGFR/p16-status estimated semiquantitatively by immunohistochemistry were included in the study. Data were evaluated by EGFR-expression (high/low) and p16-status (positive/negative) consequently dividing tumours into four groups by combination of the biomarkers. Patient/tumour characteristics and complete 5-year follow-up were available. Results: Low EGFR-expression was significantly more common in p16-positive tumours compared to p16-negative, p < 0.0001. p16 positivity showed a strong prognostic impact (p < 0.0001, HR = 0.22 [0.13-0.38]), whereas EGFR was a weak prognostic marker when local control was used as endpoint (p = 0.03, HR = 0.53 [0.29-0.94]). Combination of EGFR/p16 did not add significant information to p16 alone and by multivariable analysis only p16 showed significant prognostic information for all evaluated endpoints. Conclusions: Both EGFR and p16 bear prognostic information in oropharyngeal cancer, although p16 is, by far, the strongest prognostic factor. The markers seem to be correlated and this might have influence when evaluating the effect of EGFR inhibition in oropharyngeal tumours. (C) 2013 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 108 (2013) 489-494
引用
收藏
页码:489 / 494
页数:6
相关论文
共 29 条
  • [1] Expression of EGFR and HPV-associated p16 in head and neck cancer: correlation and influence on prognosis after radiotherapy in 1088 patients from the randomised DAHANCA 5, 6 & 7 trials
    Lassen, P.
    Eriksen, J. G.
    Tramm, T.
    Hamilton-Dutoit, S.
    Alsner, J.
    Overgaard, J.
    EJC SUPPLEMENTS, 2009, 7 (02): : 470 - 470
  • [2] A Case of HPV-Associated Oropharyngeal Squamous Cell Carcinoma with Block-Like, Partial Loss of p16 Expression
    Rasmussen, S. A.
    Lewis, J. S., Jr.
    Mirabello, L.
    Bass, S.
    Yeager, M.
    Corsten, M. J.
    Bullock, M. J.
    HEAD & NECK PATHOLOGY, 2022, 16 (04): : 1251 - 1256
  • [3] A Case of HPV-Associated Oropharyngeal Squamous Cell Carcinoma with Block-Like, Partial Loss of p16 Expression
    S. A. Rasmussen
    J. S. Lewis
    L. Mirabello
    S. Bass
    M. Yeager
    M. J. Corsten
    M. J. Bullock
    Head and Neck Pathology, 2022, 16 : 1251 - 1256
  • [4] HPV-associated p16-expression and response to radiobiological modifications of radiotherapy in head and neck cancer: results from the randomised DAHANCA trials
    Lassen, P.
    Eriksen, J. G.
    Krogdahl, A.
    Specht, L.
    Overgaard, M.
    Andersen, E.
    Johansen, J.
    Andersen, L. J.
    Overgaard, J.
    EJC SUPPLEMENTS, 2009, 7 (03): : 11 - 11
  • [5] The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: Evaluation of the randomised DAHANCA 6&7 trial
    Lassen, Pernille
    Eriksen, Jesper G.
    Krogdahl, Annelise
    Therkildsen, Marianne Hamilton
    Ulhoi, Benedicte P.
    Overgaard, Marie
    Specht, Lena
    Andersen, Elo
    Johansen, Jorgen
    Andersen, Lisbeth J.
    Grau, Cai
    Overgaard, Jens
    RADIOTHERAPY AND ONCOLOGY, 2011, 100 (01) : 49 - 55
  • [6] Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer
    Reimers, Niklas
    Kasper, Hans U.
    Weissenborn, Soenke J.
    Stuetzer, Hartmut
    Preuss, Simon F.
    Hoffmann, Thomas K.
    Speel, Ernst Jan M.
    Dienes, Hans P.
    Pfister, Herbert J.
    Guntinas-Lichius, Orlando
    Klussmann, Jens P.
    INTERNATIONAL JOURNAL OF CANCER, 2007, 120 (08) : 1731 - 1738
  • [7] IMPROVED SURVIVAL AND RESPONSE TO RADIOTHERAPY IN HPV-RELATED OROPHARYNGEAL CARCINOMAS - A SUBGROUP ANALYSIS OF THE RANDOMIZED DAHANCA 5 & 7 TRIALS
    Lassen, P.
    Eriksen, J. G.
    Tramm, T.
    Alsner, J.
    Dutoit, S. H.
    Overgaard, J.
    RADIOTHERAPY AND ONCOLOGY, 2008, 88 : S151 - S151
  • [8] Correlation of HPV16 infection and p16 expression with prognosis in patients with hypopharyngeal carcinoma
    Yang, Jun-Quan
    Wang, Hong-Bin
    Wu, Meng
    Sun, Yu-Man
    Liu, Hong-Xia
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2016, 9 (05): : 4978 - 4985
  • [9] Metastatic HPV-Associated Oropharyngeal Versus Primary Pulmonary Squamous Cell Carcinoma: is p16 Immunostain Useful?
    Jefree J. Schulte
    Jamie Steinmetz
    Larissa V. Furtado
    Aliya N. Husain
    Mark W. Lingen
    Nicole A. Cipriani
    Head and Neck Pathology, 2020, 14 : 966 - 973
  • [10] Metastatic HPV-Associated Oropharyngeal Versus Primary Pulmonary Squamous Cell Carcinoma: is p16 Immunostain Useful?
    Schulte, Jefree J.
    Steinmetz, Jamie
    Furtado, Larissa, V
    Husain, Aliya N.
    Lingen, Mark W.
    Cipriani, Nicole A.
    HEAD & NECK PATHOLOGY, 2020, 14 (04): : 966 - 973